NewAmsterdam Pharma reported total assets of $687.99M and total liabilities of $57.20M for the quarter ended Sep 2026, down 12.5% year over year. This balance sheet covers 17 quarters of results from Dec 2021 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Dec2021 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current Assets | |||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 60.13M | 467.50M | 441.31M | 416.71M | 368.31M | 340.45M | 481.15M | 430.71M | 422.73M | 771.74M | 748.42M | 563.86M | 538.41M | 490.00M | 457.61M | 424.15M | 423.13M |
| Short-term InvestmentsInvestments (Current) | 62.45M | 60.06M | 175.30M | 164.54M | 146.24M | 178.50M | 209.70M | 205.11M | |||||||||
| Cash & Current Investments | 60.13M | 467.50M | 441.31M | 416.71M | 368.31M | 340.45M | 481.15M | 430.71M | 422.73M | 834.19M | 808.48M | 739.16M | 702.95M | 636.24M | 636.11M | 633.85M | 628.24M |
| Receivables - OtherOther Receivables | 0.88M | 3.99M | 2.13M | 1.65M | 1.75M | 1.44M | 3.29M | 3.90M | 6.77M | 8.02M | 5.11M | 8.52M | |||||
| Prepaid Assets | 10.25M | 6.34M | 6.68M | 14.64M | 15.15M | 24.27M | 8.83M | 30.69M | 28.07M | 38.14M | 20.60M | 24.00M | 42.42M | ||||
| Current Assets | 66.67M | 477.74M | 423.05M | 346.79M | 487.82M | 445.35M | 437.87M | 863.41M | 817.30M | 769.85M | 732.33M | 675.70M | 658.04M | 659.21M | 672.16M | ||
| Non-Current Assets | |||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.22M | 0.15M | 0.12M | 0.05M | 0.10M | 0.23M | 0.23M | 0.24M | 0.24M | 0.31M | 0.32M | 0.38M | 0.38M | 0.41M | 0.55M | ||
| Long-Term Investments | 44.17M | 53.09M | 92.61M | 71.24M | 44.41M | 14.88M | |||||||||||
| Intangibles | 88.65M | 88.71M | |||||||||||||||
| Goodwill & Intangibles | 84.84M | 88.71M | 0.17M | 0.49M | 0.54M | 0.59M | 0.53M | 0.50M | 0.47M | 0.44M | 0.41M | 0.38M | 0.34M | 0.31M | |||
| Other Non-Current Assets | 0.16M | 0.04M | 0.02M | 0.01M | 2.59M | ||||||||||||
| Non-Current Assets | 1.03M | 88.96M | 88.94M | 0.31M | 0.64M | 1.34M | 1.32M | 1.21M | 1.11M | 45.26M | 54.10M | 93.58M | 74.60M | 45.25M | 15.82M | ||
| Assets | 67.70M | 566.71M | 511.99M | 347.10M | 488.46M | 446.69M | 439.19M | 864.62M | 818.41M | 815.11M | 786.43M | 769.28M | 732.64M | 704.45M | 687.99M | ||
| Liabilities | |||||||||||||||||
| Current Liabilities | |||||||||||||||||
| Accounts Payables | 11.13M | 19.73M | 22.66M | 16.92M | 9.97M | 10.19M | 10.58M | 13.61M | 8.02M | 9.46M | 10.10M | 15.42M | 8.09M | 10.28M | 15.46M | ||
| Payables | 11.13M | 19.73M | 22.66M | 16.92M | 9.97M | 10.19M | 10.58M | 13.61M | 8.02M | 9.46M | 10.10M | 15.42M | 8.09M | 10.28M | 15.46M | ||
| Current Deferred Revenue | 13.87M | 8.94M | 8.12M | 6.06M | 4.50M | 6.01M | 3.03M | 3.99M | 3.99M | 2.80M | 5.71M | ||||||
| Total Current Liabilities | 11.19M | 37.80M | 41.66M | 49.90M | 59.73M | 45.31M | 41.26M | 106.92M | 40.91M | 36.51M | 58.27M | 85.79M | 67.42M | 72.97M | 57.15M | ||
| Non-Current Liabilities | |||||||||||||||||
| Non-Current Deferred Revenue | 4.79M | 1.02M | 0.44M | 0.22M | |||||||||||||
| Operating Leases | 0.13M | 0.06M | 0.02M | 0.33M | 0.27M | 0.20M | 0.14M | 0.10M | 0.09M | 0.07M | 0.06M | 0.05M | |||||
| Other Non-Current Liabilities | 7.52M | 7.79M | 16.49M | 13.39M | 18.81M | ||||||||||||
| Total Non-Current Liabilities | 0.13M | 12.37M | 11.41M | 50.92M | 60.17M | 45.86M | 41.52M | ||||||||||
| Total Liabilities | 11.31M | 50.17M | 138.65M | 58.70M | 76.66M | 59.25M | 60.33M | 107.12M | 41.05M | 36.62M | 58.36M | 85.85M | 67.42M | 73.03M | 57.20M | ||
| Shareholder's Equity | |||||||||||||||||
| Common Equity | 56.39M | 516.54M | 398.41M | 373.34M | 331.84M | 288.39M | 411.80M | 387.44M | 378.86M | 757.50M | 777.36M | 778.50M | 728.07M | 683.43M | 665.22M | 631.42M | 630.78M |
| Liabilities and Shareholders Equity | 67.70M | 566.71M | 511.99M | 347.10M | 488.46M | 446.69M | 439.19M | 864.62M | 818.41M | 815.11M | 786.43M | 769.28M | 732.64M | 704.45M | 687.99M | ||
| Retained Earnings | -140.04M | -316.97M | -410.74M | -449.75M | -466.39M | -558.57M | -598.10M | -615.46M | -687.47M | -762.39M | -810.83M | -874.97M | -892.36M |
Pull NewAmsterdam Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NAMS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NAMS", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NAMS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();